Eliglustat and miglustat are indeed approved for the treatment of pediatric patients with Gaucher’s disease, the most common lipid storage disorder resulting from a genetic deficiency of the enzyme glucocerebrosidase (glucosylceramidase) [72]. The gene discussed is GBA1; the disease is Gaucher disease.